UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (32171) 32171
Newspaper Article (502) 502
Book Chapter (383) 383
Magazine Article (236) 236
Book / eBook (122) 122
Dissertation (115) 115
Book Review (37) 37
Reference (30) 30
Publication (27) 27
Trade Publication Article (21) 21
Government Document (18) 18
Web Resource (17) 17
Newsletter (9) 9
Report (8) 8
Streaming Video (8) 8
Journal / eJournal (3) 3
Manuscript (3) 3
Poster (3) 3
Art (2) 2
Paper (2) 2
Microfilm (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
castration (26550) 26550
animals (18706) 18706
male (18046) 18046
female (14666) 14666
humans (11760) 11760
rats (10040) 10040
science & technology (7906) 7906
life sciences & biomedicine (7523) 7523
prostate cancer (4405) 4405
estradiol - pharmacology (4222) 4222
testosterone - pharmacology (3388) 3388
pregnancy (3071) 3071
mice (3000) 3000
middle aged (2927) 2927
oncology (2805) 2805
abridged index medicus (2725) 2725
time factors (2478) 2478
aged (2394) 2394
old medline (2261) 2261
progesterone - pharmacology (2230) 2230
orchiectomy (2215) 2215
adult (2171) 2171
prostatic neoplasms, castration-resistant - drug therapy (1903) 1903
luteinizing hormone - blood (1780) 1780
prostate (1741) 1741
rats, inbred strains (1706) 1706
ovary - physiology (1696) 1696
androgens (1655) 1655
metastasis (1612) 1612
prostatic neoplasms, castration-resistant - pathology (1609) 1609
cancer (1587) 1587
urology & nephrology (1555) 1555
testosterone (1490) 1490
research (1488) 1488
sex factors (1442) 1442
adrenalectomy (1349) 1349
organ size (1278) 1278
castration-resistant prostate cancer (1268) 1268
neoplasm metastasis (1265) 1265
estrus (1171) 1171
prostatic neoplasms - drug therapy (1121) 1121
metastases (1064) 1064
prostatic neoplasms - pathology (1053) 1053
age factors (1049) 1049
testosterone - blood (1004) 1004
antineoplastic agents - therapeutic use (991) 991
prognosis (988) 988
chemotherapy (984) 984
care and treatment (979) 979
testis - physiology (970) 970
treatment outcome (960) 960
follicle stimulating hormone - blood (954) 954
hypophysectomy (951) 951
cell line, tumor (936) 936
endocrinology & metabolism (929) 929
analysis (919) 919
aged, 80 and over (893) 893
sexual behavior, animal - drug effects (892) 892
castration - veterinary (891) 891
body weight (879) 879
estrogens - pharmacology (871) 871
receptors, androgen - metabolism (852) 852
uterus - drug effects (848) 848
dose-response relationship, drug (837) 837
prostatic neoplasms, castration-resistant - metabolism (791) 791
veterinary sciences (760) 760
kinetics (747) 747
patients (736) 736
tritium (724) 724
ovary (722) 722
rabbits (705) 705
prostatic neoplasms, castration-resistant - genetics (702) 702
androgen receptor (697) 697
luteinizing hormone - metabolism (692) 692
tumors (684) 684
cancer therapies (665) 665
cell biology (658) 658
urology (657) 657
estrogens (652) 652
disease progression (642) 642
uterus - metabolism (626) 626
menopause (625) 625
in vitro techniques (620) 620
radioimmunoassay (618) 618
prostate - metabolism (617) 617
testosterone - metabolism (611) 611
aging (602) 602
docetaxel (599) 599
prostatic neoplasms - metabolism (597) 597
hysterectomy (596) 596
prostate - drug effects (585) 585
dogs (584) 584
research article (584) 584
retrospective studies (582) 582
prolactin - blood (581) 581
androgen antagonists - therapeutic use (572) 572
estradiol (571) 571
gene expression (571) 571
hormones (570) 570
prostatic neoplasms - therapy (561) 561
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (45) 45
Online Resources - Online (15) 15
Collection Dvlpm't (Acquisitions) - Vendor file (11) 11
UTL at Downsview - May be requested (7) 7
St. Michael's College (John M. Kelly) - 2nd Floor (6) 6
Media Commons - Microtexts (5) 5
Gerstein Science - Stacks (4) 4
UofT at Scarborough - Stacks (4) 4
Criminology - Stacks (3) 3
Regis College - Storage (3) 3
Thomas Fisher Rare Book - Rare Book (3) 3
UofT at Mississauga - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
East Asian (Cheng Yu Tung) - Stacks (2) 2
Music - Stacks (2) 2
OISE - Stacks (2) 2
Pontifical Inst. Mediaeval Studies - Library use only (2) 2
Institute for Christian Studies - Stacks (1) 1
Knox College (Caven) - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UofT at Mississauga - Oversize (1) 1
UofT at Scarborough - Oversize (1) 1
Victoria University CRRS - Library use only (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (29333) 29333
French (1184) 1184
German (1099) 1099
Russian (714) 714
Japanese (709) 709
Italian (402) 402
Spanish (297) 297
Portuguese (194) 194
Polish (124) 124
Chinese (78) 78
Dutch (59) 59
Czech (57) 57
Korean (49) 49
Hungarian (39) 39
Bulgarian (32) 32
Swedish (21) 21
Ukrainian (20) 20
Norwegian (16) 16
Romanian (14) 14
Danish (11) 11
Finnish (11) 11
Serbian (11) 11
Hebrew (10) 10
Slovak (9) 9
Croatian (8) 8
Turkish (5) 5
Afrikaans (4) 4
Arabic (3) 3
Latin (3) 3
Indonesian (2) 2
Persian (2) 2
Greek (1) 1
Hindi (1) 1
Yiddish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 04/2018, Volume 378, Issue 15, pp. 1408 - 1418
Among men with nonmetastatic prostate cancer who had a rapid PSA doubling time and were receiving androgen-deprivation therapy, the median metastasis-free... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Prostate-Specific Antigen | Double-Blind Method | Humans | Middle Aged | Proportional Hazards Models | Male | Prostatic Neoplasms, Castration-Resistant - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Prostatic Neoplasms, Castration-Resistant - pathology | Disease-Free Survival | Thiohydantoins - adverse effects | Exanthema - chemically induced | Neoplasm Metastasis - prevention & control | Thiohydantoins - therapeutic use | Aged, 80 and over | Androgen Antagonists - therapeutic use | Aged | Androgen Antagonists - adverse effects | Prostate cancer | Care and treatment | Metastasis | Medical research | Antigens | Lymphatic system | Medical imaging | Prostate-specific antigen | Research & development--R&D | Family medical history | Hypothyroidism | Survival | Patients | Metastases | Androgens | Hospitals | Castration | Prostate | Index Medicus | Abridged Index Medicus | Adenocarcinoma | pathology | Androgen Antagonists | Exanthema | 80 and over | Prostatic Neoplasms | Neoplasm Metastasis | Thiohydantoins | Urologi och njurmedicin | drug therapy | chemically induced | Castration-Resistant | prevention & control | secondary | adverse effects | Urology and Nephrology | therapeutic use
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2018, Volume 378, Issue 26, pp. 2465 - 2474
Journal Article
Cancer, ISSN 0008-543X, 09/2017, Volume 123, Issue 18, pp. 3532 - 3539
BACKGROUND Breast cancer 2 (BRCA2)‐associated breast and ovarian cancers are sensitive to platinum‐based chemotherapy. It is unknown whether BRCA2‐associated... 
DNA damage repair | prostate cancer | castration resistance | breast cancer 2 (BRCA2) | carboplatin | Life Sciences & Biomedicine | Oncology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Prostatic Neoplasms, Castration-Resistant - genetics | Prostatic Neoplasms, Castration-Resistant - pathology | Taxoids - therapeutic use | Neoplasm Metastasis | Carboplatin - therapeutic use | Neoplasm Invasiveness - pathology | Genes, BRCA2 | Germ-Line Mutation | Adult | Retrospective Studies | Genetic Predisposition to Disease | Prostatic Neoplasms, Castration-Resistant - drug therapy | Cancer Care Facilities | Prostate-Specific Antigen - blood | Disease-Free Survival | Survival Analysis | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Neoplasm Staging | Cohort Studies | Care and treatment | Chemotherapy | Usage | Men | Gene therapy | Prostate cancer | Health aspects | Cancer | Prostate-specific antigen | Metastasis | Taxane | Blood | Metastases | Gene sequencing | Confidence intervals | Castration | Platinum | Consultation | Deoxyribonucleic acid--DNA | BRCA2 protein | Antigens | Breast cancer | Tumor cell lines | Patients | Current carriers | Corrosion resistance | Carboplatin | Mutation | Prostate | DNA sequencing | Index Medicus | Abridged Index Medicus | BRCA2 | castration-resistance
Journal Article
European journal of nuclear medicine and molecular imaging, ISSN 1619-7070, 03/2018, Volume 45, Issue 3, pp. 348 - 354
Journal Article
Annals of oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1508 - 1516
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically... 
Castration-resistant prostate cancer | Biomarker | Enzalutamide | Abiraterone | Plasma DNA | Androgen receptor | Life Sciences & Biomedicine | Oncology | Science & Technology | Phenylthiohydantoin - adverse effects | Multivariate Analysis | Predictive Value of Tests | Prospective Studies | Circulating Tumor DNA - genetics | Phenylthiohydantoin - therapeutic use | Humans | Middle Aged | Male | Prostatic Neoplasms, Castration-Resistant - genetics | Patient Selection | Antineoplastic Agents, Hormonal - adverse effects | Time Factors | DNA Mutational Analysis | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Adult | Odds Ratio | Precision Medicine | Receptors, Androgen - blood | Androstenes - adverse effects | Prostatic Neoplasms, Castration-Resistant - blood | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Androstenes - therapeutic use | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Multiplex Polymerase Chain Reaction | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Disease-Free Survival | Receptors, Androgen - genetics | Aged | Biomarkers, Tumor - genetics | Prostatic Neoplasms, Castration-Resistant - mortality | Circulating Tumor DNA - blood | Mutation | Index Medicus | androgen receptor | abiraterone | Editor's Choice | castration-resistant prostate cancer | plasma DNA | biomarker | Original | enzalutamide
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 04/2016, Volume 34, Issue 12, pp. 1402 - 1418
Journal Article
European urology, ISSN 0302-2838, 11/2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer | Index Medicus
Journal Article